SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is experiencing extreme volatility and intense investor focus as the market eagerly awaits an imminent FDA PDUFA decision for its life-saving drug, Narsoplimab, to treat TA-TMA. Following a trading halt for news pending, community sentiment is largely optimistic for approval, anticipating a significant price surge fueled by high short interest and the drug's first-in-class status for a condition with no existing treatment. The broader context of the recent de-risking deal with Novo Nordisk and previous regulatory hurdles fuels speculation of substantial long-term value and even a potential buyout, making this a pivotal moment for the company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, which is touted as the largest commercial communications array ever deployed in low Earth orbit. This achievement is fueling significant bullish sentiment, with many anticipating the validation of its direct-to-device cellular broadband vision and rapid network expansion. However, discussions also reflect skepticism around the company's long-term profitability and current valuation, even as the community focuses on future scaling and execution milestones.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid a contentious Reuters report suggesting Nvidia halted 18A chip process testing, which many in the community dismiss as 'fake news' or 'FUD' designed for market manipulation. Investors are actively discussing the true implications, with many viewing recent price dips as a buying opportunity given Intel's long-term foundry strategy and the recent FTC approval of Nvidia's $5 billion investment. The broader context of Intel's manufacturing turnaround and US government support for domestic chip production remains a key talking point.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending as Sanofi has announced an all-cash agreement to acquire the company, offering a significant premium for its leading hepatitis B vaccine and promising shingles pipeline. The community is actively celebrating the immediate gains for shareholders, though some express sentiment that the valuation is conservative, fueling speculation about potential competing bids. This acquisition highlights Sanofi's strategic expansion in adult vaccines and reflects the ongoing M&A activity within the biotech sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is actively trending as investors voice deep frustration with management's perceived inaction to secure partnerships, especially for its combination flu/COVID vaccine, a sentiment exacerbated by a competitor's recent acquisition. The community debates whether leadership's prolonged silence signals advanced buyout discussions or a strategic misstep, particularly as potential regulatory scrutiny on mRNA vaccines could highlight Novavax's protein-based platform as a differentiated alternative.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as Apple CEO Tim Cook's recent stock purchase sparks significant community discussion, viewed by many as a strong vote of confidence in the company. While some dismiss the insider buy as insignificant, others believe it signals a potential turnaround for the sportswear giant, which has faced headwinds from China sales and tariff concerns.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following the FDA's expanded approval of AQVESME (mitapivat) for adults with alpha- or beta-thalassemia, establishing it as the first and only oral treatment for this condition. The community is actively discussing the commercial implications and the drug's high cost, while also reflecting on broader concerns about management's communication style and historical execution.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is a focal point of market discussion following its Marigold acquisition and upcoming CES 2026 showcase, where its AI-powered Athena platform is expected to lead future marketing innovations. Despite analysts raising price targets and impressive growth metrics, the community expresses strong sentiment that the stock remains significantly undervalued and poised for a major re-rating, with many anticipating an explosive move driven by further AI developments.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing significant buzz following its announced inclusion in the S&P MidCap 400 index, a move the community views as a major catalyst for increased institutional buying and enhanced market visibility. Investors are actively discussing its potential as a leader in Agentic AI automation, drawing comparisons to other high-growth tech plays, while some caution about near-term profit-taking.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending amidst reports of significant insider buying from its CEO, fueling discussions around its extremely low float and potential for a short squeeze. Despite concerns regarding fundamental valuation and a past DOJ investigation into its volatility, the community is actively debating if its current momentum could replicate prior parabolic surges seen in similar speculative microcaps.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Biomerica, Inc. (BMRA) traded nearly 26% lower on Wednesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biomerica.com/news/news-details/2025/Biomerica-Announces-Reverse-Stock-Split/default.aspx">said</a> it would implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock to increase its bid price.The stock split will be effective at 12:01 a.m. ET on April 21, and Biomerica’s common stock will begin trading on a split-adjusted basis when the market opens on Monday, the company said.Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock, subsequently reducing the number of outstanding shares from about 20.4 million to about 2.5 million.The move is aimed at enabling the biomedical technology company to regain compliance with the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market.To regain compliance, Biomerica’s common stock must close at or above a $1.00 per share bid price for at least ten consecutive business days prior to May 5.On Stocktwits, retail sentiment around Biomerica fell from ‘extremely bullish’ to ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’.<figure class="image"><img style="aspect-ratio:1306/306;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_1_33_21_PM_png_82a4f25b9a.webp" alt="BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1306" height="306"><figcaption>BMRA's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that today marks a good opportunity to buy the stock as the reverse split is “not that big of a deal” and the company has a strong cash runway.<stembedurl>https://stocktwits.com/ildamiano1/message/611809693</stembedurl>Biomerica’s cash and cash equivalents totaled $3.06 million as of February-end, marking an increase from $2.37 million at the end of the second quarter (Q2) of fiscal 2025.<a href="https://stocktwits.com/symbol/BMRA">BMRA stock</a> is up by about 42% year-to-date but has fallen 43% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-made-900-million-dollars-from-china-business-in-2024-report/chQPqv2RbOH">Ford Made $900M From China Business In 2024, Says Report: Retail Sentiment Brightens But Still Bearish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Biomerica Stock Slumps After Reverse Stock Split Announcement: Retail’s Disappointed

Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.

Equity

Medical diagnostic product maker Biomerica Inc. emerged as the top biotech stock with the highest jump in new retail followers on Stocktwits Friday.Shares of the nanocap company tumbled over 9% on Friday afternoon, following a 100% surge in the prior session — its best single-day performance since March 18, 2020, when the stock more than quadrupled.On Thursday, Biomerica announced that its Fortel Prostate Specific Antigen (PSA) Screening Test received approval from the UAE Ministry of Health and Prevention.&nbsp;The test offers rapid and accurate results in just 10 minutes using a simple finger-prick blood sample, measuring PSA levels, an established early marker of prostate disease.The accessible nature of the test is designed to facilitate early detection of prostate cancer and related conditions, aiming to improve patient outcomes, reduce strain on healthcare systems, and encourage proactive health management, the company said.The UAE approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.&nbsp;The company previously achieved regional success with its EZ Detect Colon Disease At-Home Screening Test, which secured government insurance reimbursement in Dubai.Biomerica said it is working to replicate this success with the Fortel PSA test, establishing partnerships with key distributors and securing regulatory approvals to improve accessibility to early cancer detection solutions.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BMRA_sentiment_and_message_volume_Jan_17_cec1cb6947.png" alt="BMRA sentiment and message volume Jan 17.png" width="1318" height="324"><figcaption>BMRA sentiment and message volume Jan 17 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Despite Friday’s stock dip, likely driven by profit-taking, retail sentiment on Stocktwits remained ‘bullish’, with a notable rise in message volume.&nbsp;Many retail investors indicated they were “buying the dip,” as chatter about the stock soared.<stembedurl>https://stocktwits.com/chaudaaary/message/600490675</stembedurl><stembedurl>https://stocktwits.com/Gunsmoke16/message/600488437</stembedurl><stembedurl>https://stocktwits.com/543688Ireland/message/600474360</stembedurl>Biomerica’s retail follower count on Stocktwits has climbed nearly 5% over the past year, while message volume has soared over a thousand-fold, even as the stock has shed more than 31% in value during the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prostate cancer cells, 3D illustration. Prostate cancer awareness image. | Image source: KATERYNA KON/SCIENCE PHOTO LIBRARY via Getty Images

Biomerica Adds Most New Retail Followers Among Biotechs After UAE Nod For Prostate Cancer Screening Test

The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

Current Price	$2.59
Prev Close	$2.62
Open	$2.63
Dividend Yield	0.00%
50-Day Moving Average	$2.56
Beta	1.08
Avg. Volume	18,395.95
PE Ratio	-1.71

52-Week High	$10.16
52-Week Low	$2.11
Market Capitalization	$7.72M
EPS (Annual)	-$2.16
Price to Book	1.43
Revenue Per Employee	$98,351.85
Enterprise Value/EBITDA	N/A

BMRA
Biomerica Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest BMRA News

BMRABiomerica Inc.